STOCK TITAN

Cyclerion Therapeutics Inc - CYCN STOCK NEWS

Welcome to our dedicated news page for Cyclerion Therapeutics (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cyclerion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cyclerion Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.16%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Cyclerion Therapeutics Inc

Nasdaq:CYCN

CYCN Rankings

CYCN Stock Data

9.13M
1.13M
20.77%
41.34%
0.81%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About CYCN

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.